DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Actemra (Tocilizumab) - Published Studies

 
 



Actemra Related Published Studies

Well-designed clinical trials related to Actemra (Tocilizumab)

Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. [2014]

Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. [2013]

Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. [2013]

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. [2012]

IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). [2012]

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. [2012]

Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. [2011.10]

Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. [2011.05]

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. [2011.03]

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. [2011.02]

Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. [2011.01]

Integrated safety in tocilizumab clinical trials. [2011]

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. [2011]

Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. [2010.12]

Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. [2010.07]

Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. [2010.07]

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. [2010.06.24]

The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. [2010.03]

Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. [2010.01]

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. [2010.01]

Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. [2010]

The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. [2010]

Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. [2010]

Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. [2010]

Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. [2010]

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. [2009.10]

Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA? [2009.03]

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. [2009]

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. [2008.11.15]

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. [2008.11]

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. [2008.10]

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. [2008.03.22]

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. [2008.03.22]

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. [2007.09]

Well-designed clinical trials possibly related to Actemra (Tocilizumab)

Biologics in Relapsing Polychondritis: A Literature Review. [2011.11.07]

New indications for biological therapies. [2011.10]

A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. [2011.10]

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. [2011.01]

Sequential use of biologic therapy in rheumatoid arthritis. [2010.05]

Sequential use of biologic therapy in rheumatoid arthritis. [2010]

A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. [2009]

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2008.01]

Other research related to Actemra (Tocilizumab)

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. [2012]

Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. [2012]

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. [2011.11.25]

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. [2011.11]

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. [2011.10]

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. [2011.09.26]

Integrated safety in tocilizumab clinical trials. [2011.09.01]

Risk of infections in rheumatoid arthritis patients treated with tocilizumab. [2011.08.24]

Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy. [2011.07]

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. [2011.07]

[Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease]. [2011.07]

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. [2011.07]

Do biologics-naive patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed? A retrospective study. [2011.03]

Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. [2011]

Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. [2011]

Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. [2011]

Clinical safety of tocilizumab in rheumatoid arthritis. [2011]

Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. [2011]

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. [2011]

Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. [2011]

Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis. [2010.09]

Tocilizumab for rheumatoid arthritis. [2010.07.07]

Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis. [2010.06.15]

Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. [2010.06]

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. [2010.06]

[Long-term treatment with a humanized anti-interleukin-6 receptor antibody (tocilizumab), improving interstitial pneumonia in a patient with multicentric Castleman disease] [2010.02]

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. [2010.02]

Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics. [2010.02]

The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. [2010.01]

Tocilizumab for rheumatoid arthritis. [2010]

The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. [2010]

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. [2010]

Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. [2009.12.19]

Tocilizumab. [2009.09]

Other possibly related research studies

The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. [2010.10]

VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery. [2010.06]

Biologics in the treatment of systemic lupus erythematosus. [2010.09]

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. [2010.06]

Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. [2010.06]

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. [2010.05.01]

IgA nephropathy associated with Castleman disease with cutaneous involvement. [2010.05]

Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? [2010.04]

Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. [2010.03]

[Rheumatoid arthritis and ankylosing spondylitis-rheumatologic highlights 2009] [2010.01.20]

Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. [2010]

Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. [2009.07]

Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. [2009.12]

ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. [2009]

Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. [2009.11]

Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? [2009.10.22]

New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals. [2009.10]

Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. [2010.02]

Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? [2009.11]

Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. [2009.10]

Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. [2009.09.01]

A clinical perspective of rheumatoid arthritis. [2009.08]

Biologic agents in rheumatoid arthritis: an update for managed care professionals. [2011.11]

Interleukin 6 inhibition - RA and beyond. [2011]

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. [2011.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014